Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal

This article was originally published in PharmAsia News

Executive Summary

Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease

You may also be interested in...



"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)

On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.

"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)

On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.

RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway

TOKYO - An executive from Massachusetts-based biotech Alnylam says its RNAi alliances with Takeda and Kyowa Hakko Kirin are well underway

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel